Get the Stockscreener App
37.27
2.36%
0.86
Harmony Biosciences Holdings Inc stock is traded at $37.27, with a volume of 516.60K.
It is up +2.36% in the last 24 hours and up +1.41% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$36.41
Open:
$36.74
24h Volume:
516.60K
Relative Volume:
0.71
Market Cap:
$2.15B
Revenue:
$772.53M
Net Income/Loss:
$180.90M
P/E Ratio:
12.01
EPS:
3.1024
Net Cash Flow:
$258.73M
1W Performance:
+2.05%
1M Performance:
+1.41%
6M Performance:
+7.50%
1Y Performance:
-3.89%
1-Day Range:
$36.16
$37.54
1-Week Range:
$36.16
$38.37
52-Week Range:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
37.27 | 2.10B | 772.53M | 180.90M | 258.73M | 3.1024 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Zacks.com featured highlights include Harmony Biosciences, Adecoagro, Sociedad Quimica y Minera de Chile, Angi and PHINIA - The Globe and Mail
Movement Recap: Is AT T Inc forming a double bottom2025 Market Trends & Fast Gain Swing Alerts - baoquankhu1.vn
5 Value Picks Amid AI-Driven Tech Sell-Off & U.S.-Iran Tensions - TradingView
Avoiding Lag: Real-Time Signals in (HRMY) Movement - Stock Traders Daily
Harmony Biosciences Makes The Grade (NASDAQ:HRMY) - Seeking Alpha
Zacks.com featured highlights include Harmony Biosciences, Universal Health Services, Concentrix and Global Payments - Yahoo Finance
CFO’s Full Share Exit Contrasts With Harmony’s Positive WAKIX Growth Story - Yahoo! Finance Canada
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2025 Earnings Call Transcript - MSN
Is Harmony Biosciences (HRMY) Pricing Reflect Its Cash Flow Potential After Recent Share Weakness - Sahm
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Short Interest Update - MarketBeat
Harmony Biosciences Chief Financial Officer Sells Shares Again After Previous Exit From Company Equity - AOL.com
Capital Management Corp VA Sells 29,654 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Harmony Biosciences CFO Fully Exits Equity Ownership - intellectia.ai
Harmony Biosciences' CFO Sells All of His Insider Shares, Worth $752,800 - Yahoo Finance
Harmony Biosciences' CFO Sells All of Her Insider Shares, Worth $752,800 - The Motley Fool
Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes" - sharewise.com
Hussman Strategic Advisors Inc. Reduces Stock Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Insider Sell: Sandip Kapadia Sells Shares of Harmony Biosciences Holdings Inc (HRMY) - GuruFocus
Sandip Kapadia Sells 3,746 Shares of Harmony Biosciences (NASDAQ:HRMY) Stock - MarketBeat
How Harmony Biosciences Can Prove Its Skeptics Wrong - Finviz
What’s the analyst consensus on Harmony Biosciences Holdings Inc.Earnings Beat & AI Powered Market Entry Ideas - Mfd.ru
Harmony Biosciences: Still Undervalued But Unappealing Risk/Reward (Downgrade) - Seeking Alpha
Is Harmony Biosciences (HRMY) Attractive After Recent Price Weakness And DCF Upside Potential? - Yahoo Finance
Evaluating Harmony Biosciences (HRMY) Valuation After Stronger Fundamentals And Breakout Signals - Yahoo Finance
Harmony Biosciences Holdings (HRMY) Investor Outlook: A Promising 24.34% Upside Potential - DirectorsTalk Interviews
Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? - Finviz
Harmony Biosciences Holdings, Inc. $HRMY Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Did Stronger Fundamentals and Bullish Technicals Just Shift Harmony Biosciences Holdings' (HRMY) Investment Narrative? - Yahoo Finance
How A New Price Target Is Reshaping The Story For Harmony Biosciences Holdings (HRMY) - Yahoo Finance
Assessing Harmony Biosciences (HRMY) Valuation As Growth, Financial Strength And Technical Signals Attract Investors - Sahm
I Was Shocked to Find This Value-Priced Biotech Growth Stock - Finviz
HRMY or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Should Value Investors Buy Harmony Biosciences (HRMY) Stock? - Yahoo Finance
Harmony Biosciences (NASDAQ:HRMY) Raised to "Strong-Buy" at Zacks Research - MarketBeat
Harmony’s WAKIX Surges Toward Blockbuster Status as Revenue Nears $1 Billion - MyChesCo
Discipline and Rules-Based Execution in HRMY Response - Stock Traders Daily
Stock Recap: Can Harmony Biosciences Holdings Inc reach all time highs this yearMarket Sentiment Report & Short-Term Trading Alerts - baoquankhu1.vn
Harmony Biosciences CFO Kapadia sells $752k in stock By Investing.com - Investing.com Nigeria
Harmony Biosciences (NASDAQ:HRMY) CFO Sells $752,919.12 in Stock - MarketBeat
Harmony Biosciences CFO Kapadia sells $752k in stock - Investing.com
Earnings Beat: Is Harmony Biosciences Holdings Inc part of any ETF2025 Key Highlights & AI Powered Market Trend Analysis - baoquankhu1.vn
Harmony Biosciences Projects WAKIX Revenue to Surpass $1 Billion in 2026 - Sleep Review
Harmony Biosciences stock drops after ZYN002 exit as 2026 Wakix sales outlook tops $1 billion - TechStock²
HRMY: WAKIX nears blockbuster status as pipeline and commercial expansion drive growth into 2026 - TradingView — Track All Markets
Harmony Biosciences (NASDAQ:HRMY) Stock Price Down 7.4%Here's Why - MarketBeat
Harmony Biosciences (HRMY) is an Incredible Growth Stock: 3 Reasons Why - sharewise.com
Buy Signal: Is Harmony Biosciences Holdings Inc. stock a buy before product launchesEarnings Miss & Precise Entry and Exit Recommendations - Bộ Nội Vụ
Harmony Biosciences projects 2026 WAKIX revenue to exceed $1 billion By Investing.com - Investing.com Nigeria
Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation - BioSpace
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Goldman Sachs - StreetInsider
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.23%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):